FLT3 and acute myeloid leukemia: Examined the use of 5‐azacytidine (AZA) with sorafenib in patients with FLT3‐mutated acute myeloid leukemia (AML) who had relapsed or were not responding to treatment. We examined 27 recently diagnosed patients with untreated FLT3‐mutant AML who were started on first‐line therapy using two different regimens of AZA plus sorafenib.